Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

462 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hepatectomy Followed by Adjuvant Chemotherapy with 3-Month Capecitabine Plus Oxaliplatin for Colorectal Cancer Liver Metastases.
Satake H, Hashida H, Tanioka H, Miyake Y, Yoshioka S, Watanabe T, Matsuura M, Kyogoku T, Inukai M, Kotake T, Okita Y, Matsumoto T, Yasui H, Kotaka M, Kato T, Kaihara S, Tsuji A. Satake H, et al. Among authors: kotake t. Oncologist. 2021 Jul;26(7):e1125-e1132. doi: 10.1002/onco.13816. Epub 2021 May 31. Oncologist. 2021. PMID: 33977607 Free PMC article.
Phase I study of primary treatment with 5-FU, oxaliplatin, irinotecan, levofolinate, and panitumumab combination chemotherapy in patients with advanced/recurrent colorectal cancer involving the wild-type RAS gene: the JACCRO CC-14 study.
Satake H, Tsuji A, Nakamura M, Ogawa M, Kotake T, Hatachi Y, Yasui H, Takagane A, Okita Y, Nakamura K, Onikubo T, Takeuchi M, Fujii M. Satake H, et al. Among authors: kotake t. Int J Clin Oncol. 2018 Jun;23(3):490-496. doi: 10.1007/s10147-017-1228-5. Epub 2018 Feb 20. Int J Clin Oncol. 2018. PMID: 29464396 Free PMC article. Clinical Trial.
Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI).
Satake H, Miki A, Kondo M, Kotake T, Okita Y, Hatachi Y, Yasui H, Imai Y, Ichikawa C, Murotani K, Hashida H, Kobayashi H, Kotaka M, Kato T, Kaihara S, Tsuji A. Satake H, et al. Among authors: kotake t. ESMO Open. 2017 Mar 9;2(1):e000130. doi: 10.1136/esmoopen-2016-000130. eCollection 2017. ESMO Open. 2017. PMID: 28761726 Free PMC article.
The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer.
Nishimura M, Toyoda M, Takenaka K, Imamura Y, Chayahara N, Kiyota N, Mukohara T, Kotake T, Tsuji A, Saito K, Saito Y, Minami H. Nishimura M, et al. Among authors: kotake t. Cancer Chemother Pharmacol. 2016 Jun;77(6):1165-70. doi: 10.1007/s00280-016-3026-6. Epub 2016 Apr 21. Cancer Chemother Pharmacol. 2016. PMID: 27100735 Free PMC article.
Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC study.
Kikawa Y, Kotake T, Tsuyuki S, Kang Y, Takahara S, Fujimoto Y, Yamashiro H, Yoshibayashi H, Takada M, Yasuoka R, Nakatsukasa K, Yamagami K, Suwa H, Okuno T, Nakayama I, Kato T, Ogura N, Moriguchi Y, Ishiguro H, Kagimura T, Taguchi T, Sugie T, Toi M. Kikawa Y, et al. Among authors: kotake t. Breast Cancer. 2022 Sep;29(5):796-807. doi: 10.1007/s12282-022-01357-x. Epub 2022 Apr 23. Breast Cancer. 2022. PMID: 35460066
462 results